Kinemed Inc. | Date: 2012-04-30
Hydrocarbon stapling of apolipoprotein mimetic peptides increases the helicity of the peptides, enhances their ability to promote cholesterol efflux by multiple mechanisms and makes them resistant to proteolysis. Hydrocarbon stapled amphipathic helical peptides are useful in the treatment of cardiovascular diseases and other disorders.
Hellerstein M.,Kinemed Inc. |
Hellerstein M.,University of California at Berkeley |
Hellerstein M.,University of California at San Francisco |
Turner S.,Kinemed Inc.
Current Opinion in Lipidology | Year: 2014
Purpose of Review: Reverse cholesterol transport (RCT) is considered a significant component of the atheroprotective effects of HDL. Methods for quantifying flux through the RCT pathway have not been available until recently. There is a need to improve our understanding of HDL function, including the role of RCT in general and individual steps of RCT in particular, on atherosclerosis. This review highlights new information about cholesterol flux through the RCT pathway. RECENT FINDINGS: Recent clinical studies have demonstrated several important quantitative features of cholesterol fluxes in vivo, providing insight into variability and control of specific components of the RCT pathway. The findings illustrate the independent nature of individual steps in the RCT pathway and their apparently weak relationship to plasma HDL cholesterol levels. Nonclinical studies provide some mechanistic data re-enforcing the importance of apoB particles in RCT and role roles for serum albumin and erythrocytes in free cholesterol flux. These findings suggest that the HDL-centric view of RCT may need revision. SUMMARY: The constellation of known lipoproteins and other players involved in this pathway continues to increase. Further research, particularly in humans, is needed in order to understand which parts of the RCT pathway are most relevant to the pathophysiology and treatment of atherosclerosis. © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Kinemed Inc. | Date: 2015-09-17
The present invention relates to novel diagnostic, prognostic, predictive and pharmacodynamic properties with regard to amyotrophic lateral sclerosis (ALS) and/or Parkinsons disease (PD) with and without dementia components. The methods described herein will prove very useful in the development of diagnostic as well as treatment strategies for patients with amyotrophic lateral sclerosis (ALS) and/or Parkinsons disease (PD).
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 225.09K | Year: 2013
Myocardial fibrosis is a crucial marker of adverse cardiac remodeling. Research suggests a strong correlationbetween the extent of myocardial fibrosis and adverse myocardial remodeling that occurs after ischemic injury orduring the progression of cardiomyopathies and heart failure. Diffuse myocardial fibrosis is thought to provide a high-risk substrate for the development of atrial and ventricular arrhythmias. Therefore, early detection of myocardialfibrosis might be prognostic for the development of heartfailure and increased risk of both atrial and ventricular heartrhythm disorders. In addition, a means to easily assess the development of myocardial fibrosis is expected to providea more effective way to monitor therapeutic efficacy of interventions intended to slow or halt the progression of thesecardiac disorders. Although present methods can detect frank fibrosis, new methods that target the early stages offibrogenesis are expected to be extremely useful as they may be more effective in guiding interventions that blockfurther development of fibrosis and prevent the onset of myocardial remodeling associated with heart failure andarrhythmias. PUBLIC HEALTH RELEVANCE
Kinemed Inc. and The United States Of America | Date: 2015-07-31
The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre- HDL, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines TNF-, IL-1, and/or IL-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed.
Glaxosmithkline and Kinemed Inc. | Date: 2012-12-06
The present invention is based on the finding that enrichment of D3-creatinine in a urine sample following oral administration of a single defined dose of D3-creatine can be used to calculate total-body creatine pool size and total body skeletal muscle mass in a subject. The invention further encompasses methods for detecting creatinine and D3-creatinine in a single sample. The methods of the invention find use, inter alia, in diagnosing disorders related to skeletal muscle mass, and in screening potential therapeutic agents to determine their effects on muscle mass.
News Article | May 12, 2015
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor biology to new therapeutics for retinal disease and cancer, today announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director of the company and will work closely with Iconic’s leadership team as a Senior Scientific Advisor. Dr. Hirth has over 30 years of biotechnology and pharmaceutical discovery and development experience and currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, and Afferent Pharmaceuticals. From 2001 to 2013 at Plexxikon, Dr. Hirth built a novel, structure-guided drug discovery platform, which brought several new chemical entities into the clinic, including Zelboraf™, an FDA-approved therapy for metastatic melanoma together with a companion diagnostic. From 1991-2000, as Sugen Inc.’s president and founder, Dr. Hirth was instrumental in building the company from its inception and in advancing several kinase inhibitors through clinical trials in oncology. Prior to Sugen, he was Vice President of Research at Boehringer Mannheim where he successfully led the company’s erythropoietin program to approval in 1989. Dr. Hirth was a research scientist with the Max Planck Institute. He completed his post-doctoral work at the University of California, San Diego and received his PhD in molecular genetics from Heidelberg University, Germany. Dr. Hirth commented, “Iconic’s approach to targeting Tissue Factor biology is unique, and the Phase 1 wet AMD data are compelling. In addition, Tissue Factor is also an important oncology target. Because it is overexpressed in some but not all tumors, Tissue Factor may offer a personalized approach to medicine while covering a wide range of tumors. Similarly, from a business perspective, I believe that extending Iconic’s research into oncology enhances the value proposition." According to William Greene, M.D., Chief Executive Officer of Iconic, “Dr. Hirth brings to Iconic a rare combination of scientific expertise, drug development prowess and proven business acumen. We look forward to his contributions as we implement our corporate and product strategies, build our research organization and evaluate the opportunities for tissue factor-directed therapeutics.” Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and angiogenesis together, ICON-1 may potentially alter the course of this leading cause of blindness. Iconic has completed a Phase 1 clinical trial in wet AMD and has initiated a Phase 2 study in newly diagnosed AMD patients. The company is investigating the ICON family of proteins in cancer and has initiated a research program in solid tumors. Iconic is backed by leading venture capital firms MPM Capital, H.I.G. Bioventures and Lundbeckfond Ventures. Please visit www.iconictherapeutics.com for additional information.
News Article | October 28, 2014
KineMed, Inc. and the U.S. Army Research Institute of Environmental Medicine’s (USARIEM) Military Nutrition Division announced today they are entering into a partnership to examine KineMed’s platform technology to assess skeletal muscle protein synthesis and muscle mass in Warfighters. The U.S. military seeks to better understand muscle adaptive responses to operational stressors in order to identify nutritional requirements and strategies that promote musculoskeletal health and resilience. “We are honored that the U.S. Army is applying our tests of muscle mass and function to optimize support of its Warfighters,” said David Fineman, CEO & Chairman of KineMed. This collaborative project will use KineMed’s state-of-the-art proteomic and stable isotope techniques to examine predictive responses indicative of changes in skeletal muscle protein synthesis and/or skeletal muscle mass in response to operational stressors including energy deficit, energy surplus, military training, and deployment to harsh environments and alterations in field and garrison feeding programs. “This partnership anchors our strategy to broadly expand our Muscle and Health Division,” Fineman added. KineMed is a life sciences company that has developed a platform technology with broad applications in drug development and medical diagnosis. Using its patented technology, KineMed has developed analytic biomarker tests that measure, in a single sample, the rate of change of critical biological pathways. KineMed has the unique ability to measure the production and destruction of key molecules involved in health and disease-modifying biological processes to provide meaningful, and previously unavailable, information to transform healthcare decisions. KineMed’s Muscle and Health Division is led by William Evans, Ph.D., a world leader in muscle metabolism and nutrition. Disclaimer: The opinions or assertions contained herein are the private views of the author(s) and are not to be construedas official or as reflecting the views of the Army or the Department of Defense. For more information about KineMed, please visit: www.kinemed.com.
News Article | November 5, 2014
KineMed, Inc. (www.kinemed.com) announced today that it has been awarded a three-year grant by the Bill & Melinda Gates Foundation to apply its novel, proprietary non-invasive measurement of skeletal muscle mass to pre-term and full-term infants and young children. The Principal Investigator, William Evans, Ph.D., is head of the KineMed Division of Muscle and Health. The study will, for the first time, measure changes in skeletal muscle mass during one year of growth. The information from this project will provide new information to better assess the effects of nutritional status and other factors that result in the loss of muscle. Childhood malnutrition and growth stunting have possible long-term consequences on the capacity of individuals to reach their full adult potential. According to the World Health Organization in 2013, 161.5 million children worldwide under the age of 5 experience growth stunting. “Growth stunting and malnutrition/kwashiorkor remain problems of enormous public health importance throughout the world. Muscle mass is perhaps the most sensitive metric of growth stunting, but there had not been a simple field measurement test for muscle mass before now,” said Marc Hellerstein, M.D., Ph.D., President and Chief Scientific Officer of KineMed. “We at KineMed are very excited about working with the Gates Foundation to develop and validate our test of muscle mass in this setting.” KineMed is a life sciences company that has developed a platform technology with broad applications in drug development and medical diagnosis. Using its patented technology, KineMed has developed analytic biomarker tests that measure, in a single sample, the rate of change of critical biological pathways. KineMed has the unique ability to measure the production and destruction of key molecules involved in health and disease-modifying biological processes to provide meaningful, and previously unavailable, information to transform healthcare decisions. For more information about KineMed, please visit: www.kinemed.com.